CA2885762C - Inhibitors of beta-hydroxylase for treatment of cancer - Google Patents
Inhibitors of beta-hydroxylase for treatment of cancer Download PDFInfo
- Publication number
- CA2885762C CA2885762C CA2885762A CA2885762A CA2885762C CA 2885762 C CA2885762 C CA 2885762C CA 2885762 A CA2885762 A CA 2885762A CA 2885762 A CA2885762 A CA 2885762A CA 2885762 C CA2885762 C CA 2885762C
- Authority
- CA
- Canada
- Prior art keywords
- amino
- furanone
- substituted
- unsubstituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704014P | 2012-09-21 | 2012-09-21 | |
| US61/704,014 | 2012-09-21 | ||
| PCT/US2013/061050 WO2014047519A2 (en) | 2012-09-21 | 2013-09-20 | Inhibitors of beta-hydrolase for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2885762A1 CA2885762A1 (en) | 2014-03-27 |
| CA2885762C true CA2885762C (en) | 2022-05-03 |
Family
ID=50342080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2885762A Active CA2885762C (en) | 2012-09-21 | 2013-09-20 | Inhibitors of beta-hydroxylase for treatment of cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US9771356B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3345596B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6469009B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102137180B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN104902889A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013317791B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2885762C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2660822T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1208805A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014047519A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3345596B1 (en) | 2012-09-21 | 2021-01-20 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
| WO2019012159A1 (en) * | 2017-07-14 | 2019-01-17 | Protea Biopharma N.V. | METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE |
| WO2019246093A1 (en) * | 2018-06-18 | 2019-12-26 | Midwestern University | Monoclonal antibodies targeting epitopes of asph |
| CN109364251A (zh) * | 2018-12-06 | 2019-02-22 | 苏州大学 | Tet蛋白在治疗抑郁症中的应用 |
| CA3130396A1 (en) | 2019-02-15 | 2020-08-20 | Midwestern University | Isotopically-stabilized tetronimide compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD39717A (cg-RX-API-DMAC7.html) | ||||
| DE39717C (de) | H. LEHMANN in München, Enhuberstr. 5 part | Bleistifthalter | ||
| DE3577384D1 (de) | 1985-08-02 | 1990-06-07 | Chevron Res | Unkrautvertilgende 2-(oxa- oder thiaheterozyklische) 5-amino-3-oxo-4-(substituierte phenyl)-2,3-dihydrofurane. |
| US5314913A (en) | 1992-12-08 | 1994-05-24 | American Home Products Corporation | 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones |
| US5698585A (en) | 1995-04-13 | 1997-12-16 | Kikkoman Corporation | Pharmaceutical preparation for prevention and/or treatment for cataract |
| JPH09110853A (ja) * | 1995-10-12 | 1997-04-28 | Kikkoman Corp | ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法 |
| UA57002C2 (uk) * | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| DE69816047T2 (de) | 1997-03-14 | 2004-04-22 | Merck Frosst Canada & Co, Kirkland | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US20050123545A1 (en) | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| WO2003018575A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| AU2002950862A0 (en) | 2002-08-19 | 2002-09-12 | Biosignal Pty Ltd | Furanone derivatives and methods of making same |
| WO2004035812A2 (en) | 2002-10-16 | 2004-04-29 | Isis Innovation Limited | Asparaginyl hydroxylases and modulators thereof |
| ES2383115T3 (es) * | 2004-01-09 | 2012-06-18 | Eli Lilly And Company | Compuestos de tiofeno y furano |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| JP5855095B2 (ja) * | 2010-06-07 | 2016-02-09 | ノボメディックス, エルエルシーNovomedix, Llc | フラニル化合物およびその使用 |
| EP3345596B1 (en) | 2012-09-21 | 2021-01-20 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
-
2013
- 2013-09-20 EP EP17202827.6A patent/EP3345596B1/en not_active Not-in-force
- 2013-09-20 CA CA2885762A patent/CA2885762C/en active Active
- 2013-09-20 WO PCT/US2013/061050 patent/WO2014047519A2/en not_active Ceased
- 2013-09-20 WO PCT/US2013/060934 patent/WO2014047447A2/en not_active Ceased
- 2013-09-20 EP EP13838498.7A patent/EP2897607B1/en not_active Not-in-force
- 2013-09-20 JP JP2015533237A patent/JP6469009B2/ja not_active Expired - Fee Related
- 2013-09-20 CN CN201380061004.4A patent/CN104902889A/zh active Pending
- 2013-09-20 CN CN201910949656.0A patent/CN110818660B/zh not_active Expired - Fee Related
- 2013-09-20 US US14/430,101 patent/US9771356B2/en active Active
- 2013-09-20 KR KR1020157010188A patent/KR102137180B1/ko not_active Expired - Fee Related
- 2013-09-20 ES ES13838498.7T patent/ES2660822T3/es active Active
- 2013-09-20 AU AU2013317791A patent/AU2013317791B2/en not_active Ceased
- 2013-09-20 HK HK15109523.0A patent/HK1208805A1/xx unknown
- 2013-09-20 ES ES17202827T patent/ES2865412T3/es active Active
-
2017
- 2017-07-17 US US15/651,842 patent/US10106532B2/en active Active
- 2017-09-26 US US15/715,989 patent/US10710995B2/en active Active
-
2018
- 2018-09-14 US US16/131,275 patent/US10351555B2/en active Active
-
2019
- 2019-06-12 US US16/439,253 patent/US10787445B2/en active Active
-
2020
- 2020-06-02 US US16/890,680 patent/US20200361925A1/en not_active Abandoned
- 2020-09-23 US US17/029,127 patent/US20210032233A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,472 patent/US20220251076A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220251076A1 (en) | Inhibitors of Beta-Hydoxylase for Treatment of Cancer | |
| CN102015606A (zh) | IRE-1α抑制剂 | |
| TWI321564B (en) | Amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2h-chromen-6-yl derivatives rocess and intermediate products for their preparation and medicaments containing these compounds | |
| US10961211B2 (en) | Isotopically-stabilized tetronimide compounds | |
| US12594261B2 (en) | Use of heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases | |
| WO2020253352A1 (zh) | 一种化合物及其制备方法和应用 | |
| US20210052561A1 (en) | Targeting aspartate beta-hydroxylase suppresses tumor malignancy and metastasis | |
| CN121449590A (zh) | 一种吲哚类化合物及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180918 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251211 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260325 |